Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PENICILLIN G POTASSIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PENICILLIN G POTASSIUM IN PLASTIC CONTAINER.
LAROTID vs PENICILLIN G POTASSIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Penicillin G is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
2-4 million units IV every 4 hours for moderate to severe infections; up to 24 million units/day for serious infections (meningitis, endocarditis).
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.5–1 hour (normal renal function). Prolonged in renal impairment (up to 7–10 hours in anuria).
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal: 60–90% unchanged via tubular secretion and glomerular filtration. Biliary/fecal: <10%.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic